Sernova Corp. (Sernova), a Canadian-based medical technology company, board has appointed Dr. Philip Toleikis as the president and chief executive officer (CEO) of the Corporation. Toleikis has more than 20 years of research, intellectual property, management and business experience in the pharmacology and biotechnology sectors. Most recently, he was as vice president, R&D pharmacology and drug screening, for Angiotech Pharmaceuticals, Inc.
At Angiotech Pharmaceuticals, Inc, he built a major scientific and information technology team that included senior scientists, research scientists and technicians. Toleikis’ major achievements at Angiotech included successful completion of Phase II European Clinical Trials, chairing the Joint Research Committee, in-licensing and out-licensing of technologies, and management of key patents and patent applications. Toleikis is the author of multiple issued patents and over 110 patent applications. His research training and experience includes biochemical pharmacology, diabetes, oncology, inflammatory diseases (psoriasis, multiple sclerosis, surgical adhesions, Alzheimer’s disease and rheumatoid arthritis), osteoarthritis, neurological diseases and cardiovascular conditions including ischemic heart disease, cardiomyopathy, hypertension and aneurysms. Dr. Toleikis will be presenting on the Corporation’s behalf at the BioFinance Conference in Toronto on Wednesday, April 29, 2009.
George Adams, chairman of the board of directors, welcomed Toleikis, stating, Sernova is privileged to now be led by such a distinguished scientist and executive. We are fully confident that Dr. Toleikis will drive our technology through the worldwide regulatory process and into commercialization. The treatment of insulin-dependent diabetes will be just the first commercial application of our platform technology. On behalf of the Board of Directors and our shareholders, I welcome Dr. Toleikis to the Sernova family.